TABLE 2.
Characteristics of adverse reactions after COVID‐19 vaccination a
| Total (n = 2290) | First dose | Total (n = 2189) | Second dose | |||||
|---|---|---|---|---|---|---|---|---|
| CoronaVac (n = 2097) | BioNTech (n = 183) | p value | CoronaVac (n = 2060) | BioNTech (n = 119) | p value | |||
| Local injection site reactions | 908 (39.7%) | 747 (35.6%) | 159 (86.9%) | <0.001 | 849 (38.8%) | 735 (35.7%) | 112 (94.1%) | <0.001 |
| Pain | 678 (29.6%) | 547 (26.1%) | 130 (71.0%) | <0.001 | 515 (23.5%) | 445 (21.6%) | 68 (57.1%) | <0.001 |
| Erythema | 124 (5.4%) | 80 (3.8%) | 43 (23.5%) | <0.001 | 56 (2.6%) | 46 (2.2%) | 8 (6.7%) | 0.008 |
| Edema | 117 (5.1%) | 88 (4.2%) | 29 (15.8%) | <0.001 | 64 (2.9%) | 58 (2.8%) | 6 (5.0%) | 0.159 |
| Systemic reactions | 739 (32.3%) | 650 (31.0%) | 85 (46.4%) | <0.001 | 700 (32.0%) | 641 (31.1%) | 55 (46.2%) | 0.002 |
| Fatigue | 411 (17.9%) | 350 (16.7%) | 58 (31.7%) | <0.001 | 263 (12.0%) | 236 (11.5%) | 26 (21.8%) | 0.001 |
| Headache | 341 (14.9%) | 297 (14.2%) | 44 (24.0%) | 0.001 | 206 (9.4%) | 189 (9.2%) | 17 (14.3%) | 0.064 |
| Myalgia | 250 (10.9%) | 207 (9.9%) | 41 (22.4%) | <0.001 | 172 (7.9%) | 149 (7.2%) | 22 (18.5%) | <0.001 |
| Fever | 57 (2.5%) | 38 (1.8%) | 18 (9.8%) | <0.001 | 29 (1.3%) | 21 (1.0%) | 8 (6.7%) | <0.001 |
| Nausea/diarrhea | 32 (1.4%) | 22 (1.0%) | 10 (5.5%) | <0.001 | 9 (0.4%) | 8 (0.4%) | 1 (0.8%) | 0.397 |
| Early anaphylaxis | 2 (0.09%) | 1 (0.05%) | 1 (0.5%) | 0.157 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| Late anaphylaxis | 1 (0.04%) | 0 (0.0%) | 1 (0.5%) | 0.083 | 1 (0.05%) | 0 (0.0%) | 1 (0.8%) | 0.055 |
| Non‐local cutaneous reactions | 94 (4.1%) | 60 (2.9%) | 33 (18.0%) | <0.001 | 81 (3.7%) | 73 (3.5%) | 6 (5.0%) | 0.442 |
| Diagnosed by | ||||||||
| Dermatologist | 85 (90.4%) | 53 (88.3%) | 31 (93.9%) | 0.540 | 79 (97.5%) | 71 (97.3%) | 6 (100%) | 1.000 |
| Emergency physician | 9 (9.6%) | 7 (11.7%) | 2 (6.1%) | 2 (2.5%) | 2 (2.7%) | 0 (0.0%) | ||
| Diagnosis | ||||||||
| Herpes zoster | 17 (0.7%) | 9 (0.4%) | 8 (4.4%) | <0.001 | 10 (0.5%) | 10 (0.5%) | 0 (0.0%) | 1.000 |
| Pityriasis rosea | 12 (0.5%) | 9 (0.4%) | 3 (1.6%) | 0.065 | 15 (0.7%) | 12 (0.6%) | 3 (2.5%) | 0.045 |
| Petechial rash | 1 (0.05%) | 1 (0.05%) | 0 (0.0%) | 1.000 | – | – | – | – |
| Dyshidrotic eczema | 4 (0.2%) | 2 (0.1%) | 2 (1.1%) | 0.035 | 1 (0.05%) | 1 (0.05%) | 0 (0.0%) | 1.000 |
| Urticaria/angioedema within 24 hours | 6 (0.3%) | 4 (0.2%) | 2 (1.1%) | 0.078 | 6 (0.3%) | 6 (0.3%) | 0 (0.0%) | 1.000 |
| Urticaria/angioedema after 24 hours | 15 (0.7%) | 12 (0.6%) | 3 (1.6%) | 0.113 | 19 (0.9%) | 18 (0.9%) | 1 (0.8%) | 1.000 |
| Lichenoid reaction | 2 (0.1%) | 2 (0.1%) | 0 (0.0%) | 1.000 | 2 (0.1%) | 2 (0.1%) | 0 (0.0%) | 1.000 |
| Erythromelalgia | 1 (0.05%) | 0 (0.0%) | 1 (0.5%) | 0.080 | – | – | – | |
| Contact dermatitis | 9 (0.4%) | 7 (0.3%) | 2 (1.1%) | 0.159 | 8 (0.4%) | 7 (0.3%) | 1 (0.8%) | 0.358 |
| Delayed large local reaction | 8 (0.4%) | 1 (0.05%) | 7 (3.8%) | <0.001 | 1 (0.05%) | 1 (0.05%) | 0 (0.0%) | 1.000 |
| SDRIFE | 1 (0.05%) | 1 (0.05%) | 0 (0.0%) | 1.000 | – | – | – | |
| Disseminated herpes zoster | 1 (0.05%) | 0 (0.0%) | 1 (0.5%) | 0.080 | – | – | – | |
| Disseminated herpes simplex | – | – | – | – | 1 (0.05%) | 1 (0.05%) | 0 (0.0%) | 1.000 |
| Acneiform eruption | 1 (0.05%) | 0 (0.0%) | 1 (0.5%) | 0.080 | – | – | – | – |
| Maculopapular rash | 9 (0.4%) | 7 (0.3%) | 2 (1.1%) | 0.159 | 9 (0.4%) | 8 (0.4%) | 1 (0.8%) | 0.393 |
| Erythroderma | 1 (0.05%) | 0 (0.0%) | 1 (0.5%) | 0.080 | – | – | – | – |
| Bullous pemphigoid | 2 (0.1%) | 2 (0.1%) | 0 (0.0%) | 1.000 | – | – | – | – |
| Chilblain | – | – | – | – | 2 (0.1%) | 2 (0.1%) | 0 (0.0%) | 1.000 |
| Cutaneous vasculitis | – | – | – | – | 2 (0.1%) | 2 (0.1%) | 0 (0.0%) | 1.000 |
| Psoriasis vulgaris | 2 (0.1%) | 1 (0.05%) | 1 (0.5%) | 0.154 | 3 (0.1%) | 2 (0.1%) | 1 (0.8%) | 0.153 |
| Cutaneous sarcoidosis | – | – | – | – | 1 (0.05%) | 0 (0.0%) | 1 (0.8%) | 0.054 |
| Linear IgA bullous dermatosis | – | – | – | – | 1 (0.05%) | 1 (0.05%) | 0 (0.0%) | 1.000 |
Abbreviations: SDRIFE, symmetrical drug‐related intertriginous and flexural exanthema.
a
Type of vaccine not known for four of the local injection reactions, eight of the systemic reactions, and three of the non‐local cutaneous reactions.